Stakeholders Again Seek Consensus On LDTs As Congress Weighs Options

February 11, 2016 at 5:55 PM

With the expected release of final FDA guidance on regulation of laboratory developed tests growing closer and the prospect of legislation dimming, stakeholders are making what some view as a last ditch attempt to reach consensus on where to draw the line between FDA and CMS oversight of LDTs.


Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.